Navigation Links
Dyadic International Raises $3 Million in Private Placement of Convertible Notes
Date:8/24/2010

JUPITER, Fla., Aug. 24 /PRNewswire-FirstCall/ -- Dyadic International, Inc. ("Dyadic") (Pink Sheets: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced that it has completed a private placement of $3,000,000 in convertible subordinated secured promissory notes (the "Notes") with two investors.

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20091214/DYADICLOGO)

The Notes will pay interest quarterly at a rate of 8% per annum. The Notes will be convertible, at the holder's option after January 1, 2011, into shares of Dyadic common stock at a conversion price of $1.82 which represents 120% of the average closing price for the 30-day period preceding the closing date. The Notes mature on January 1, 2013.

Dyadic expects to use proceeds from this offering for working capital including continued investments in research and development and new product introductions, and general corporate purposes.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "This financing provides Dyadic with a timely source of capital on terms that are substantially less dilutive for Dyadic's stockholders than other capital raising alternatives. The proceeds of this offering strengthen Dyadic's balance sheet and improves our working capital which puts Dyadic in a better position to negotiate additional licensing arrangements and strategic collaborations on the best possible terms for the benefit of Dyadic and its stockholders."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International to Announce Second Quarter 2010 Financial Results and Hold Conference Call on August 13, 2010
2. Dyadic International Announces Final Resolution and Dismissal of Stockholder Class Action Lawsuit
3. Dyadic International Engages The Abraham Group as Strategic Advisor
4. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
5. Dyadic International Strengthens Management Team
6. Dyadic International Extends Collaboration With The Scripps Research Institute
7. Nutrastar International Inc. Announces Record Second Quarter 2010 Results
8. International Society for Cellular Therapy (ISCT) joins forces with Roche and Genzyme to launch Cell Therapy Industry Partnership.
9. Renhuang Receives AAA(1) Rating from Chinese Academy of International Trade & Economic Cooperation of Ministry of Commerce
10. SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents
11. FRC Systems International State-of-the-art Industrial Wastewater Treatment Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... - BioAmber Inc. (NYSE: BIOA ), a leader ... & Co. Ltd., its partner in the ... an additional CDN$25 million in the joint venture for ... to 40%.  Mitsui will also play a stronger role ... Sarnia , providing dedicated resources alongside BioAmber,s ...
(Date:2/10/2016)... 10, 2016  The Maryland House of Delegates and ... that University of Maryland School of Medicine Dean ... of Maryland Medical System President and CEO Robert ... the highest honor given to the public by the ... Dean Reece and Mr. Chrencik for their contributions ...
(Date:2/10/2016)... WASHINGTON , Feb.10, 2016 ASAE is ... and Association Management Companies (AMC) the option of joining ... flat annual fee determined by staff size, every employee ... to join ASAE and reap all available member benefits.   ... CAE. "Our new organizational membership options will allow organizations ...
(Date:2/10/2016)...  IsoRay, Inc. (NYSE MKT: ISR), a medical technology ... applications for the treatment of prostate, brain, lung, head ... results for the second quarter and six months of ... --> --> Revenue was ... which ended December 31, 2015, a 12% increase compared ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases ... from Vigilant Solutions. Brian Wenberg explains, ... victim was walking out of a convenience store and witnessed an elderly male ... vehicle, striking his vehicle and leaving the scene.  In ...
(Date:2/2/2016)... 2, 2016 This BCC Research report ... by reviewing the recent advances in high throughput ... the field forward. Includes forecast through 2019. ... challenges and opportunities that exist in the bioinformatic ... developers, as well as IT and bioinformatics service ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
Breaking Biology News(10 mins):